drugset / Trial / NCT01620554

Dose-range Finding Study of BF2.649 Effect on Patients With Obstructive Sleep Apnea (OSA)

NCT01620554

Phase 2 Completed 110 enrolled Bioprojet
RandomizedParallel-groupDouble-blindTreatment

Summary

Prospective, multicenter, double-blind, phase II, randomized, dose-response study in 5 parallel groups (dose-range).

Timeline

Start
2010-10
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Pitolisant Small molecule 5 mg Oral
Subject Pitolisant Small molecule 10 mg Oral
Subject Pitolisant Small molecule 20 mg Oral
Subject Pitolisant Small molecule 40 mg Oral